Samsung Biologics posts 35% Q4 revenue rise as plants run full
South Korean CDMO Samsung Biologics (KRX: 207940) said fourth-quarter 2025 revenue rose 35% year-on-year to 1,286 billion won ($877 million), with operating profit up 68% to 528 billion won, as the firm's key Plants 1–3 and Plant 4 continue to run at full utilization.
The company said EBITDA for the quarter rose 60% to 624 billion won. For full-year 2025, revenue increased 30% to 4,557 billion won and operating profit rose 57% to 2,069 billion won, which Samsung Biologics attributed to stable operations and expanded project execution across its manufacturing network.
The firm framed the quarter as one where demand continued to reward scale. The company said it signed a 1.1 trillion won manufacturing agreement with a European pharmaceutical company in Q4 and that cumulative contract value has now exceeded $21 billion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze